Daily intranasal oxytocin for 28 days showed no significant effects on brain structure or social behavior in three autism-related mouse models, though it did normalize a grooming deficit in one strain.
No significant social improvementacross all three autism mouse models after 28 days of daily intranasal oxytocin, despite advanced MRI and behavioral testing
What the researchers found
Across three autism-related mouse models (16p11.2 deletion, Shank3 knockout, Fmr1 knockout), chronic intranasal oxytocin (0.6 IU daily for 28 days) did not produce significant changes in neuroanatomy as measured by structural MRI, though some trending effects were observed.
No significant effect on social behavior was found in any strain. The only significant behavioral finding was normalization of a grooming deficit in the Fmr1 knockout model. No other treatment effects survived multiple comparisons correction. The authors conclude that chronic oxytocin had limited effects, and no promising pattern of treatment susceptibility by genotype emerged.
Why it matters
This is an important negative result. Oxytocin has generated enormous public and scientific interest as a potential autism treatment, but this well-designed, multi-model study found very limited benefits. Negative results like these are essential for guiding the field away from ineffective approaches and toward more promising therapies. The finding that different genetic backgrounds didn't show different responses also dampens hopes for genotype-guided oxytocin therapy.
How the study worked
Large randomized, blinded, placebo-controlled preclinical study. Three autism mouse models received intranasal oxytocin (0.6 IU) or placebo daily for 28 days starting at 5 weeks of age. Brain structure was assessed with longitudinal in vivo T1-weighted MRI (90 μm resolution) and high-resolution ex vivo T2-weighted MRI (40 μm resolution) using deformation-based morphometry. Behavior was tested across multiple domains including social and repetitive behaviors.
What this study cannot tell us
Mouse models of autism have inherent limitations in replicating human autism, which is far more heterogeneous. The dose (0.6 IU) and 28-day duration may not capture effects that require different dosing or longer treatment. Intranasal delivery to the mouse brain may not mirror human intranasal delivery. The study examined three specific genetic models, which may not represent all forms of autism.
How to read the evidence
This is a rigorously designed preclinical study: randomized, blinded, placebo-controlled, with three genetic models, longitudinal imaging, and multiple behavioral measures. It represents high-quality preclinical evidence, though translation to human autism involves additional complexity.
When this study was published
Published in 2022 in NeuroImage, this study adds to the evolving understanding of oxytocin's limited therapeutic potential for autism, a topic that continues to be debated.
The bigger picture
This study adds to a growing body of evidence questioning oxytocin's therapeutic potential for autism. Despite early enthusiasm from small human trials, the translational gap has widened. This preclinical study's rigorous design — randomized, blinded, placebo-controlled, with multiple genetic models — makes its negative findings particularly informative for the field. It suggests the autism research community should redirect resources toward other therapeutic targets.
Questions still open
- Would longer treatment duration or different oxytocin doses produce different results?
- Are there other autism subtypes or genetic backgrounds where oxytocin might still be effective?
- Should the clinical research community reconsider the investment in oxytocin trials for autism given accumulating negative data?
Common questions
Does oxytocin help with autism?
Why test three different mouse models?
Read the original research
Examining the effect of chronic intranasal oxytocin administration on the neuroanatomy and behavior of three autism-related mouse models.
NeuroImage, 257, 119243
Citation
Lindenmaier, Zsuzsa; Ellegood, Jacob; Stuive, Monique; Easson, Kaitlyn; Yee, Yohan; Fernandes, Darren; Foster, Jane; Anagnostou, Evdokia; Lerch, Jason P. (2022). Examining the effect of chronic intranasal oxytocin administration on the neuroanatomy and behavior of three autism-related mouse models.. NeuroImage, 257, 119243. https://doi.org/10.1016/j.neuroimage.2022.119243